Download Files:
GNF2133
$480 – $3,900
Products Details
Product Description
– GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes[1].
Web ID
– HY-142295
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C24H30N6O2
References
– [1]Liu YA, et al. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133. J Med Chem. 2020 Mar 26;63(6):2958-2973.
CAS Number
– 2561414-56-8
Molecular Weight
– 434.53
Compound Purity
– 98.49
SMILES
– CCN1CCN(CC1)C(NC2=NC=CC(C3=CN(C4=CN=CC=C34)C5CCOCC5)=C2)=O
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease
Solubility
– DMSO : 4 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– DYRK
Isoform
– DYRK1
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
